NCT00318630 is a Phase 1 clinical trial of Rosiglitazone in Asthma, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00318630?

NCT00318630 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00318630?

Interventions in NCT00318630: Rosiglitazone, Placebo.

Is NCT00318630 still recruiting?

NCT00318630 is currently completed. Last updated 25 September 2017.

Last reviewed 2017-09-25 · How we verify

NCT00318630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect Of AVANDIA On The Late Asthmatic Response

Completed Phase 1 Last updated 25 September 2017

What this trial tests

Phase 1 trial testing Rosiglitazone in Asthma in 26 participants. Completed in 30 June 2006.

Timeline

22 July 2005

Primary endpoint
30 June 2006

30 June 2006

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Primary purpose	treatment
Enrollment	26
Start date	22 July 2005
Primary completion	30 June 2006
Estimated completion	30 June 2006
Sites	1 location across New Zealand

Drugs / interventions tested

Rosiglitazone (ROSIGLITAZONE) — full drug profile →
Placebo

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to investigate the effects of AVANDIA on the asthmatic response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.
Richards DB, Bareille P, Lindo EL, Quinn D, et al · · 2010 · cited 44× · PMID 19944580 · DOI 10.1016/j.rmed.2009.11.006

Verify or expand the search:

Other trials of Rosiglitazone

Trials testing the same drug.

NCT04114136 — Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies · Phase 2 · recruiting
NCT03309319 — A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas · NA · unknown
NCT01287598 — BAY73-4506 Probe Substrate Study · Phase 1 · completed
NCT00964106 — Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation · Phase 1 · completed
NCT00679939 — Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health · Phase 4 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00318630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 25 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00318630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing